TMCnet News
PeptiDream Announces the Appointment of Dr. Kiyofumi Kaneshiro to the Management Team at PeptiDream Inc.PeptiDream Inc., a Kanagawa-based biopharmaceutical company ("PeptiDream")(TOKYO:4587) announced today, the appointment of Dr. Kiyofumi Kaneshiro to the management team at PeptiDream. Dr. Kaneshiro has a unique balance of a strong scientific background coupled with a wealth of healthcare industry experience in management, strategy, and organization. Prior to joining PeptiDream, Dr. Kaneshiro was a Partner and Managing Director at The Boston Consulting Group (BCG). At BCG, Dr. Kaneshiro worked predominantly with clients in the pharmaceutical and medtech sectors. He led a broad range of projects in his 11+ year career at BCG, including corporate growth strategy development, M&A strategy development, new business launch, and R&D productivity enhancement. At PeptiDream, in his role as Executive Vice President, Dr. Kaneshiro will work side-by-side President Dr. Patrick C. Reid and Executive Vice President Dr. Keiichi Masuya to manage and direct ll scientific, strategic, and business efforts at PeptiDream. Dr. Kaneshiro received his PhD from the University of Tokyo in 2005 in Oncology and Cancer Biology.
[Comment from Dr. Patrick C. Reid, President & CEO of PeptiDream Inc]
[Comment from Dr. Kiyofumi Kaneshiro, Executive Vice President of
PeptiDream Inc] Over the past seven years, PeptiDream has established funded discovery collaborations with 18 leading pharmaceutical companies; Amgen, AstraZeneca, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Novartis, Mitsubishi (News - Alert) Tanabe, Daiichi Sankyo, Merck & Co.(USA), Sanofi, Teijin, Kyorin, Ipsen, Genentech, Shionogi, Asahi Kasei, Janssen, and Bayer all of which are active and ongoing. In addition, PeptiDream has transferred its PDPS discovery platform for broad use to Bristol-Myers-Squibb, Novartis, Lilly, Genentech, and Shionogi.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180111006258/en/ |